N/A
Completed N=789
Treatment of Patients With Chronic Hepatitis C With PegIntron as Monotherapy or in Combination With Ribavirin (Study P04437)(COMPLETED)
Hepatitis C, Chronic · Hepacivirus
Source: ClinicalTrials.gov NCT00705666 ↗
Enrolled (actual)
789
Serious AEs
8.4%
Results posted
Jun 2010
Primary outcomePrimary: The Number of Participants Receiving the Recommended Treatment Duration (24 Weeks for Genotypes 2 and 3 and 48 Weeks for Genotype 1 According to the French 2002 Consensus Meeting). — 160; 195 Participants
Summary
In February 2002, a French Consensus Conference on the management of patients with chronic hepatitis C in France was organized. The jury issued several recommendations on pegylated alpha interferon/ribavirin treatment strategy. Three years after these recommendations, it is of interest to understand the evolution of hepatitis C management in France in real clinical practice. This observational study will permit the identification of patients who are treated and will provide information on the use of PegIntron/ Ribavirin.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Number of Participants Receiving the Recommended Treatment Duration (24 Weeks for Genotypes 2 and 3 and 48 Weeks for Genotype 1 According to the French 2002 Consensus Meeting). |
160; 195 | — |
Eligibility Criteria
Inclusion Criteria
- Adult participants starting a treatment with PegIntron for the treatment of chronic hepatitis C.
Exclusion Criteria
- Concomitant participation in a clinical trial for the treatment of hepatitis C.
Data sourced from ClinicalTrials.gov (NCT00705666). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.